Chimeracom Management Team

Richard M. Kream, Ph.D.

Dr. Richard M. Kream (Ph.D., Albert Einstein College of Medicine) is Chimeracom’s Science Director and the creator of Chimeracom’s intellectual property. He is a Professor of Bio-Chemistry, SUNY Downstate Medical Center. Before moving to Downstate, Dr. Kream was a Professor of Anesthesiology, Biochemistry and Pharmacology at Tufts Medical School. He has spent his career studying pain and addiction medicine. He has published many articles in peer reviewed scientific journals. In addition, he serves as a reviewer for the National Institutes of Health reviewing grants for the Brain Disorder and Clinical Neuroscience study section.

Pamela L. Esposito, Ph.D.

Dr. Pamela L. Esposito (Ph.D., Tufts Univ.) is Chimeracom’s Chief Operating Officer. Dr. Esposito, a protégé of Dr. Kream, supervises the effort to develop Elpis Pharmaceuticals's compounds. Dr. Esposito is dedicated to achieving Chimeracom’s goal of relieving pain suffering without tolerance formation and decreasing addiction potential.

John J. Witmeyer III, J.D.

John J. Witmeyer III (J.D., Duke Univ.) is Managing Director responsible for strategic planning, intellectual property and business negotiations. He has been a member of the New York and District of Columbia bars for more than thirty years, whose legal practice encompasses complex business transactions and litigation, including intellectual property, international, antitrust, corporate and securities law. He also served in the US Army’s Chemical Corps, retiring from the reserve force as a Colonel, Chemical Corps, US Army. He is a biographee in Who’s Who in America.

Thomas R. Esposito, J.D.

Thomas R. Esposito (J.D., Fordham Univ.), is Managing Director and Chief Legal Officer of Chimeracom. He has more than thrity years' experience in corporate and litigation legal practice.